REGENT PACIFIC (00575): Deep Longevity Expands U.S. Operations and Appoints Key Executives Ahead of 2026

Stock News
2025/12/10

REGENT PACIFIC (00575) announced that Deep Longevity, Inc., a global leader in explainable AI-driven aging clocks and longevity science, along with its subsidiaries (collectively "Deep Longevity"), has appointed Dylan Kay as Chief Commercial Officer for the United States and Luke Shaffer as Vice President of Sales for the U.S. Both executives will assume their roles on January 1, 2026.

This strategic hiring marks Deep Longevity's proactive entry into the U.S., the world's largest healthcare market, with commercial operations set to launch in Q1 2026. Mr. Kay brings over 15 years of experience scaling enterprise health tech and digital therapy platforms, having recently driven nine-figure growth at Livongo (now part of Teladoc Health) and OneDrop. Mr. Shaffer previously led partnerships with Fortune 500 employers and health plans at a major corporate health services provider.

Together, they will spearhead sales and partnership development across four key areas: • Corporate health and wellness programs • Health insurance and risk-bearing entities • Diagnostic labs and longevity clinics • Premium consumer health platforms

Deep Longevity's clinically validated aging clocks—including BloodAge, EpigeneticAge, MindAge, BiometricAge, and the upcoming FaceAge—deliver multimodal, actionable insights into molecular, physiological, cognitive, and psychological aging. Its SaaS solutions empower employers and insurers to shift from reactive disease care to quantifiable, personalized longevity programs proven to extend healthspan and reduce long-term costs.

Deepankar Nayak, CEO of Deep Longevity, stated, "Currently, 90% of the U.S.'s $4.5 trillion annual healthcare spending stems from chronic diseases. Dylan and Luke are proven leaders who have repeatedly translated emerging science into enterprise-scale impact. Under their leadership, we are poised to position deep aging clocks at the core of America’s preventive healthcare revolution."

Deep Longevity has set an ambitious target to onboard over 50 U.S. corporate clients by the end of 2026.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10